A new generation of anticoagulants, namely Xarelto and Pradaxa, have been at the center of much controversy in recent times. The manufacturers of these drugs have seen a significant increase in sales of their drugs, thanks in part to how convenient they are compared to more traditional blood thinners. However, the significant sales of these drugs...
Since December 2014, all federal Xarelto lawsuits have been consolidated in the Eastern District of Louisiana. Any federal lawsuits filed against Janssen Pharmaceuticals and Bayer AG, the manufacturers of Xarelto (rivaroxaban), would have been transferred to the Louisiana court for pre-trial proceedings. By moving all cases into one court, federal judges expect to increase efficiency...
In the recent June 2015 issue of JAMA Ophthalmology, researchers studied some of Xarelto’s disturbing side effects, further calling into question the safety of the drug. These scientists studied the link between Xarelto usage and the possibility of an increase in stomach bleeds and eye hemorrhaging. Drs. Judy H. Hun and John C. Hwang found that patients...
A recent study has revealed that mothers who take Xarelto can pass down the drug to their unborn child. When ingested during pregnancy, the anticoagulant transfers back and forth across the placenta between a mother and her fetus. The study was done by a research team at The Motherisk Program at the Hospital for Sick...
Xarelto, the blockbuster anticoagulant that was approved by the FDA in 2011, has recently seen an increase in sales even as the drug continues to cause problems for a significant number of patients. In the first quarter of 2015, both Xarelto sales and J& J pharmaceutical division sales increased by 3% to $7.7 billion. Bayer...
Xarelto, a relatively new prescription blood thinner, was first approved by the FDA in 2011 for patients who were at risk of developing blood clots as a result of knee or hip replacement surgeries. The marketers of the anticoagulant, Janssen Pharmaceuticals, aggressively marketed the drug as a “one-size-fits-all” drug. Given that, doctors readily prescribed the...
Foreign regulators in Australia are questioning whether additional blood monitoring on new anticoagulants would make the drugs safer. These drugs include Pradaxa, Eliquis and more specifically, Xarelto. The Australian Therapeutic Goods Administration recently announced this month that it had completed a review of new oral anticoagulants like Xarelto and have concluded that regular blood monitoring...
Press Room ©2025 Nachawati Law Group
